Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Autoimmune Disorders

  Free Subscription


Articles published in Acta Neurol Scand

Retrieve available abstracts of 67 articles:
HTML format
Text format



Single Articles


    December 2017
  1. ZECCA C, Antozzi CG, Torri Clerici V, Ferrazzini M, et al
    Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.
    Acta Neurol Scand. 2017 Dec 3. doi: 10.1111/ane.12882.
    PubMed     Text format     Abstract available


  2. HEESEN C, Haase R, Melzig S, Poettgen J, et al
    Perceptions on the value of bodily functions in multiple sclerosis.
    Acta Neurol Scand. 2017 Dec 3. doi: 10.1111/ane.12881.
    PubMed     Text format     Abstract available


    November 2017
  3. IBRAHIM J, Grapperon AM, Manfredonia F, van den Bergh PY, et al
    Serial electrophysiology in Guillain-Barre syndrome: A retrospective cohort and case-by-case multicentre analysis.
    Acta Neurol Scand. 2017 Nov 21. doi: 10.1111/ane.12872.
    PubMed     Text format     Abstract available


  4. ZETTERBERG H
    Fluid biomarkers for microglial activation and axonal injury in multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:15-17.
    PubMed     Text format     Abstract available


  5. LYCKE J
    Trials of antivirals in the treatment of multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:45-48.
    PubMed     Text format     Abstract available


  6. CELIUS EG
    Infections in patients with multiple sclerosis: Implications for disease-modifying therapy.
    Acta Neurol Scand. 2017;136 Suppl 201:34-36.
    PubMed     Text format     Abstract available


  7. WEKERLE H
    Nature, nurture, and microbes: The development of multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:22-25.
    PubMed     Text format     Abstract available


  8. FREDERIKSEN JL, Topsoe Mailand M
    Vaccines and multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:49-51.
    PubMed     Text format     Abstract available


  9. WENDEL-HAGA M, Celius EG
    Is the hygiene hypothesis relevant for the risk of multiple sclerosis?
    Acta Neurol Scand. 2017;136 Suppl 201:26-30.
    PubMed     Text format     Abstract available


    August 2017
  10. WALLIN MT, Culpepper WJ, Maloni H, Kurtzke JF, et al
    The Gulf War era multiple sclerosis cohort: 3. Early clinical features.
    Acta Neurol Scand. 2017 Aug 22. doi: 10.1111/ane.12810.
    PubMed     Text format     Abstract available


    July 2017
  11. ANDERSEN O, Hildeman A, Longfils M, Tedeholm H, et al
    Diffusion tensor imaging in multiple sclerosis at different final outcomes.
    Acta Neurol Scand. 2017 Jul 25. doi: 10.1111/ane.12797.
    PubMed     Text format     Abstract available


    June 2017
  12. GUAN Z, Shang L, Zhang W, Guo Y, et al
    A rating scale for the severity of Guillain-Barre syndrome.
    Acta Neurol Scand. 2017 Jun 14. doi: 10.1111/ane.12786.
    PubMed     Text format     Abstract available


  13. OTTO M, Markvardsen L, Tankisi H, Jakobsen J, et al
    The electrophysiological response to immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy.
    Acta Neurol Scand. 2017;135:656-662.
    PubMed     Text format     Abstract available


    May 2017
  14. MENTIS AA, Dardiotis E, Grigoriadis N, Petinaki E, et al
    Viruses and endogenous retroviruses in multiple sclerosis: From correlation to causation.
    Acta Neurol Scand. 2017 May 23. doi: 10.1111/ane.12775.
    PubMed     Text format     Abstract available


    April 2017
  15. MARTINELLI V, Dalla Costa G, Messina MJ, Di Maggio G, et al
    Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes.
    Acta Neurol Scand. 2017 Apr 9. doi: 10.1111/ane.12761.
    PubMed     Text format     Abstract available


    March 2017
  16. ELKJAER ML, Molnar T, Illes Z
    Teriflunomide for multiple sclerosis in real-world setting.
    Acta Neurol Scand. 2017 Mar 20. doi: 10.1111/ane.12755.
    PubMed     Text format     Abstract available


  17. SCHNEIDER R, Bellenberg B, Kleiter I, Gold R, et al
    Cervical cord and ventricle affection in neuromyelitis optica.
    Acta Neurol Scand. 2017;135:324-331.
    PubMed     Text format     Abstract available


    February 2017
  18. ENSARI I, Pilutti LA, Motl RW
    Depressive symptomology in multiple sclerosis: Disability, cardiorespiratory fitness and heart rate variability.
    Acta Neurol Scand. 2017 Feb 26. doi: 10.1111/ane.12748.
    PubMed     Text format     Abstract available


    January 2017
  19. LUNDELL H, Svolgaard O, Dogonowski AM, Romme Christensen J, et al
    Spinal cord atrophy in anterior-posterior direction reflects impairment in multiple sclerosis.
    Acta Neurol Scand. 2017 Jan 10. doi: 10.1111/ane.12729.
    PubMed     Text format     Abstract available


  20. VOLDSGAARD A, Koch-Henriksen N, Magyari M, Sellebjerg F, et al
    Early safety and efficacy of fingolimod treatment in Denmark.
    Acta Neurol Scand. 2017;135:129-133.
    PubMed     Text format     Abstract available


    December 2016
  21. KARAMYAN A, Brandtner H, Grinzinger S, Chroust V, et al
    Causes of death in critically ill multiple sclerosis patients.
    Acta Neurol Scand. 2016 Dec 23. doi: 10.1111/ane.12724.
    PubMed     Text format     Abstract available


  22. TANASESCU R, Midgley A, Robins RA, Constantinescu CS, et al
    Decreased interferon-beta induced STAT-4 activation in immune cells and clinical outcome in multiple sclerosis.
    Acta Neurol Scand. 2016 Dec 5. doi: 10.1111/ane.12715.
    PubMed     Text format     Abstract available


  23. D'HOOGHE MB, Haentjens P, Van Remoortel A, De Keyser J, et al
    Self-reported levels of education and disability progression in multiple sclerosis.
    Acta Neurol Scand. 2016;134:414-419.
    PubMed     Text format     Abstract available


  24. LITMEIER S, Pruss H, Witsch E, Witsch J, et al
    Initial serum thyroid peroxidase antibodies and long-term outcomes in SREAT.
    Acta Neurol Scand. 2016;134:452-457.
    PubMed     Text format     Abstract available


  25. SIMPSON S JR, Tan H, Otahal P, Taylor B, et al
    Anxiety, depression and fatigue at 5-year review following CNS demyelination.
    Acta Neurol Scand. 2016;134:403-413.
    PubMed     Text format     Abstract available


    November 2016
  26. PEARSON JF, Alla S, Clarke G, Mason DF, et al
    Multiple Sclerosis impact on employment and income in New Zealand.
    Acta Neurol Scand. 2016 Nov 28. doi: 10.1111/ane.12714.
    PubMed     Text format     Abstract available


  27. SOELBERG SORENSEN P
    Safety concerns and risk management of multiple sclerosis therapies.
    Acta Neurol Scand. 2016 Nov 27. doi: 10.1111/ane.12712.
    PubMed     Text format     Abstract available


    October 2016
  28. ZETTL UK, Schreiber H, Bauer-Steinhusen U, Glaser T, et al
    Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis.
    Acta Neurol Scand. 2016 Oct 30. doi: 10.1111/ane.12705.
    PubMed     Text format     Abstract available


  29. GOUVEIA A, Dias SP, Santos T, Rocha H, et al
    Cognitive impairment and magnetic resonance imaging correlates in primary progressive multiple sclerosis.
    Acta Neurol Scand. 2016 Oct 24. doi: 10.1111/ane.12702.
    PubMed     Text format     Abstract available


  30. ETEMADIFAR M, Mehrabi B, Kiani-Peykani R, Abtahi SH, et al
    Soil heavy metals are associated with the distribution of multiple sclerosis in Isfahan, Iran.
    Acta Neurol Scand. 2016;134:292-9.
    PubMed     Text format     Abstract available


    September 2016
  31. PUZ P, Lasek-Bal A, Radecka P
    Transcranial sonography of subcortical structures in patients with multiple sclerosis.
    Acta Neurol Scand. 2016 Sep 18. doi: 10.1111/ane.12689.
    PubMed     Text format     Abstract available


  32. ROMMER PS, Suhnel A, Konig N, Zettl UK, et al
    Coping with multiple sclerosis-the role of social support.
    Acta Neurol Scand. 2016 Sep 12. doi: 10.1111/ane.12673.
    PubMed     Text format     Abstract available


  33. BRENNER P, Piehl F
    Fatigue and depression in multiple sclerosis: pharmacological and non-pharmacological interventions.
    Acta Neurol Scand. 2016;134 Suppl 200:47-54.
    PubMed     Text format     Abstract available


  34. ROCCA MA, De Meo E, Filippi M
    Functional MRI in investigating cognitive impairment in multiple sclerosis.
    Acta Neurol Scand. 2016;134 Suppl 200:39-46.
    PubMed     Text format     Abstract available


  35. PENNER IK
    Evaluation of cognition and fatigue in multiple sclerosis: daily practice and future directions.
    Acta Neurol Scand. 2016;134 Suppl 200:19-23.
    PubMed     Text format     Abstract available


  36. MUCKSCHEL M, Beste C, Ziemssen T
    Immunomodulatory treatments and cognition in MS.
    Acta Neurol Scand. 2016;134 Suppl 200:55-9.
    PubMed     Text format     Abstract available


  37. BERGER T
    Immunological processes related to cognitive impairment in MS.
    Acta Neurol Scand. 2016;134 Suppl 200:34-8.
    PubMed     Text format     Abstract available


  38. PAUL F
    Pathology and MRI: exploring cognitive impairment in MS.
    Acta Neurol Scand. 2016;134 Suppl 200:24-33.
    PubMed     Text format     Abstract available


  39. PORTACCIO E
    Differential diagnosis, discerning depression from cognition.
    Acta Neurol Scand. 2016;134 Suppl 200:14-8.
    PubMed     Text format     Abstract available


  40. HAMALAINEN P, Rosti-Otajarvi E
    Cognitive impairment in MS: rehabilitation approaches.
    Acta Neurol Scand. 2016;134 Suppl 200:8-13.
    PubMed     Text format     Abstract available


  41. VAN ETTINGER-VEENSTRA H
    Cumulative evidence for MS as a neural network disconnection syndrome consistent with cognitive impairment mechanisms and the confounding role of fatigue and depression-outlook from the Fourth Nordic MS symposium.
    Acta Neurol Scand. 2016;134 Suppl 200:4-7.
    PubMed     Text format     Abstract available


    August 2016
  42. VAGBERG M, Axelsson M, Birgander R, Burman J, et al
    Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society.
    Acta Neurol Scand. 2016 Aug 24. doi: 10.1111/ane.12667.
    PubMed     Text format     Abstract available


  43. CAROTENUTO A, Iodice R, Petracca M, Inglese M, et al
    Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex(R).
    Acta Neurol Scand. 2016 Aug 8. doi: 10.1111/ane.12660.
    PubMed     Text format     Abstract available


    June 2016
  44. RONNING OM, Tornes KD
    Need for symptomatic management in advanced multiple sclerosis.
    Acta Neurol Scand. 2016 Jun 29. doi: 10.1111/ane.12631.
    PubMed     Text format     Abstract available


  45. MOCCIA M, Palladino R, Lanzillo R, Triassi M, et al
    Predictors of the 10-year direct costs for treating multiple sclerosis.
    Acta Neurol Scand. 2016 Jun 29. doi: 10.1111/ane.12630.
    PubMed     Text format     Abstract available


  46. AIVO J, Kurki S, Sumelahti ML, Hanninen K, et al
    Risk of osteoporotic fractures in multiple sclerosis patients in southwest Finland.
    Acta Neurol Scand. 2016 Jun 22. doi: 10.1111/ane.12623.
    PubMed     Text format     Abstract available


  47. ZHOU JY, Xu B, Lopes J, Blamoun J, et al
    Hashimoto encephalopathy: literature review.
    Acta Neurol Scand. 2016 Jun 20. doi: 10.1111/ane.12618.
    PubMed     Text format     Abstract available


  48. SKIERLO S, Rommer PS, Zettl UK
    Symptomatic treatment in multiple sclerosis-interim analysis of a nationwide registry.
    Acta Neurol Scand. 2016 Jun 9. doi: 10.1111/ane.12612.
    PubMed     Text format     Abstract available


    May 2016
  49. SIMONSEN CS, Edland A, Berg-Hansen P, Celius EG, et al
    High prevalence and increasing incidence of multiple sclerosis in the Norwegian county of Buskerud.
    Acta Neurol Scand. 2016 May 30. doi: 10.1111/ane.12615.
    PubMed     Text format     Abstract available


  50. KOLASA M, Hagman S, Verkkoniemi-Ahola A, Airas L, et al
    Anti-JC virus seroprevalence in a Finnish MS cohort.
    Acta Neurol Scand. 2016;133:391-7.
    PubMed     Text format     Abstract available


    April 2016
  51. PRESS R, Hiew FL, Rajabally YA
    Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence base and clinical practice.
    Acta Neurol Scand. 2016;133:228-38.
    PubMed     Text format     Abstract available


  52. HOLMOY T, Esbensen QY, Torkildsen O, Wergeland S, et al
    WT1 and interferon-beta-vitamin D association in MS: a longitudinal study.
    Acta Neurol Scand. 2016;133:309-12.
    PubMed     Text format     Abstract available


    March 2016
  53. VON RHEIN B, Wagner J, Widman G, Malter MP, et al
    Suspected antibody negative autoimmune limbic encephalitis: outcome of immunotherapy.
    Acta Neurol Scand. 2016 Mar 4. doi: 10.1111/ane.12575.
    PubMed     Text format     Abstract available


    February 2016
  54. SANTANGELO G, Sacco R, Siciliano M, Bisecco A, et al
    Anxiety in Multiple Sclerosis: psychometric properties of the State-Trait Anxiety Inventory.
    Acta Neurol Scand. 2016 Feb 1. doi: 10.1111/ane.12564.
    PubMed     Text format     Abstract available


    January 2016
  55. MILLER E, Kostka J, Wlodarczyk T, Dugue B, et al
    Whole-body cryostimulation (cryotherapy) provides benefits for fatigue and functional status in multiple sclerosis patients. A case-control study.
    Acta Neurol Scand. 2016 Jan 18. doi: 10.1111/ane.12557.
    PubMed     Text format     Abstract available


    January 2015
  56. ANDERSEN O
    Conclusion: National incidence and risk factor assessments may become a basis for the evaluation of prevention trials - prospects from the Third Nordic MS Symposium.
    Acta Neurol Scand. 2015;132:71-5.
    PubMed     Text format     Abstract available


  57. AIRAS L
    Hormonal and gender-related immune changes in multiple sclerosis.
    Acta Neurol Scand. 2015;132:62-70.
    PubMed     Text format     Abstract available


  58. SUNDSTROM P, Salzer J
    Vitamin D and multiple sclerosis-from epidemiology to prevention.
    Acta Neurol Scand. 2015;132:56-61.
    PubMed     Text format     Abstract available


  59. CORREALE J, Gaitan MI
    Multiple sclerosis and environmental factors: the role of vitamin D, parasites, and Epstein-Barr virus infection.
    Acta Neurol Scand. 2015;132:46-55.
    PubMed     Text format     Abstract available


  60. BOSTROM I, Landtblom AM
    Does the changing sex ratio of multiple sclerosis give opportunities for intervention?
    Acta Neurol Scand. 2015;132:42-5.
    PubMed     Text format     Abstract available


  61. BERG-HANSEN P, Celius EG
    Socio-economic factors and immigrant population studies of multiple sclerosis.
    Acta Neurol Scand. 2015;132:37-41.
    PubMed     Text format     Abstract available


  62. GRYTTEN N, Torkildsen O, Myhr KM
    Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades.
    Acta Neurol Scand. 2015;132:29-36.
    PubMed     Text format     Abstract available


  63. MYHR KM, Grytten N, Torkildsen O, Wergeland S, et al
    The Norwegian Multiple Sclerosis Registry and Biobank.
    Acta Neurol Scand. 2015;132:24-8.
    PubMed     Text format     Abstract available


  64. MAGYARI M
    Role of socio-economic and reproductive factors in the risk of multiple sclerosis.
    Acta Neurol Scand. 2015;132:20-3.
    PubMed     Text format     Abstract available


  65. HILLERT J, Stawiarz L
    The Swedish MS registry - clinical support tool and scientific resource.
    Acta Neurol Scand. 2015;132:11-9.
    PubMed     Text format     Abstract available


  66. KOCH-HENRIKSEN N, Magyari M, Laursen B
    Registers of multiple sclerosis in Denmark.
    Acta Neurol Scand. 2015;132:4-10.
    PubMed     Text format     Abstract available


  67. ANDERSEN O
    Nordic MS Epidemiology. Introduction.
    Acta Neurol Scand. 2015;132:1-3.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: